Should you buy PDL BioPharma stock? (NasdaqGS:PDLI). Let's see how it does in our automated value investing analysis system.
Based on historical returns, we believe that PDL BioPharma can grow its free cash at a rate of about 10%. That's positive!
(PDL BioPharma stock price per share)
||PDLI Fair Price
(based on intrinsic value)
||PDLI Safety Price (based on a variable margin of safety)||$16.42|
||PE Ratio versus Sector||79% lower than other Healthcare stocks|
|PE Ratio versus Industry||92% lower than other Biotechnology stocks|
|Free Cash Flow Jitter||50%|
We believe that PDL BioPharma may be worth examining further. It's making money, which is a very positive sign. Is it on sale?
Even better, PDL BioPharma looks like a stock on sale. Based on our analysis—if the company keeps making money the way it has been—you may be looking at a bargain. Keep this stock in mind as you put together your portfolio! See Before You Buy for your next steps (and read our disclaimer about investing risk).
Does PDL BioPharma have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
Most Popular Articles